Visual Outcomes of Anti-VEGF Treatment on Neovascular Age-Related Macular Degeneration: A Real-World Population-Based Cohort Study
PHARMACEUTICALS(2023)
摘要
Neovascular age-related macular degeneration (nAMD) leads to visual impairment if not treated promptly. Intravitreal anti-VEGF drugs have revolutionized nAMD treatment in the past two decades. We evaluated the visual outcomes of anti-VEGF treatment in nAMD. A real-life population-based cohort study. The data included parameters for age, sex, age at diagnosis, laterality, chronicity, symptoms, visual outcomes, lens status, and history of intravitreal injections. A total of 1088 eyes (827 patients) with nAMD were included. Visual acuity was stable or improved in 984 eyes (90%) after an average of 36 +/- 25 months of follow-up. Bevacizumab was the first-line drug in 1083 (99.5%) eyes. Vision improved >= 15 ETDRS letters in 377 (35%), > 5 ETDRS letters in 309 (28%), and was stable (>= 5 ETDRS letters) in 298 (27%) eyes after anti-VEGF treatment. The loss of 5 <= 15 ETDRS letters in 44 (4%) eyes and >= 15 ETDRS letters in 60 (6%) eyes was noted. At the diagnosis of nAMD, 110 out of 827 patients (13%) fulfilled the criteria for visual impairment, whereas 179 patients (22%) were visually impaired after the follow-up. Improvement or stabilization in vision was noted in 90% of the anti-VEGF-treated eyes with nAMD. In addition, anti-VEGF agents are crucial in diminishing nAMD-related visual impairment.
更多查看译文
关键词
neovascular age-related macular degeneration,visual outcomes,anti-VEGF,visual impairment,population-based cohort
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要